[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536338":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":106,"collaborators":108,"id":118,"slug":119,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":10,"eligibilityCriteria":124,"healthyVolunteers":120,"sex":125,"minAge":126,"maxAge":10,"enrollmentInfo":127,"targetDuration":10,"studyType":130,"phases":10,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Interni hematologicka klinika FNKV","NETWORK",[8,12,15,18,21,24],{"label":9,"type":10,"description":11,"interventionNames":10},"Standard first line treatment, stages I or II without risk factors",null,"Standard first-line treatment that includes 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and involved site radiotherapy of 20 Gy in early clinical stages I or II without risk factors.",{"label":13,"type":10,"description":14,"interventionNames":10},"Patients \u003C 60 years, stages I or II and 1 risk factor","Patients below 60 years in intermediate clinical stages I or II with at least one risk factor are treated with 2 cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) escalated and 2 cycles of ABVD in PET-4 negative cases. Involved site radiotherapy of 30 Gy is indicated in PET-4 positive patients with intermediate stages after chemotherapy.",{"label":16,"type":10,"description":17,"interventionNames":10},"Patients \u003C 60 years, stages III or IV with MMT and\u002For EN disease","Patients in advanced stages III or IV and patients in stage IIB with massive mediastinal tumor and\u002For extranodal disease are treated with 4 or 6 cycles of BEACOPP escalated based on PET-2 negativity or positivity.",{"label":19,"type":10,"description":20,"interventionNames":10},"Elderly patients ≥ 60 years and 1 risk factor","Elderly patients in intermediate stages are treated with 2 cycles of ABVD and 2 cycles of AVD without bleomycin and involved site radiotherapy of 30 Gy.",{"label":22,"type":10,"description":23,"interventionNames":10},"Elderly patients ≥ 60 years, stages III or IV","Elderly patients in advanced stages are treated with 2 cycles of ABVD and 4 cycles of AVD without bleomycin",{"label":25,"type":10,"description":26,"interventionNames":10},"Relapsed patients up to 65 years","The treatment for patients in relapse up to the age of 65 years is two cycles of platinum based salvage chemotherapy: cisplatin, cytarabine and dexamethasone (DHAP) or ifosfamide, carboplatin, etoposide (ICE) followed by high- dose chemotherapy and autologous stem cell transplantation (ASCT).",[28],{"name":29,"affiliation":30,"role":31},"Heidi Mocikova, M.D., Ph.D.","Faculty Hospital Kralovske Vinohrady","STUDY_CHAIR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","+420267163554","heidi.mocikova@fnkv.cz",{"name":38,"role":34,"phone":39,"phoneExt":10,"email":40},"Ondrej Havranek, assoc. prof.","+420325873029","ondrej.havranek@lf1.cuni.cz",[42,59,73,88,95],{"facility":43,"status":44,"city":45,"state":10,"zip":46,"country":47,"countryCode":10,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"University Hospital Hradec Kralove","RECRUITING","Hradec Králové","50005","Czechia",{"type":49,"coordinates":50},"Point",[51,52],15.83277,50.20923,{"lat":52,"lon":51},[55],{"name":56,"role":34,"phone":57,"phoneExt":10,"email":58},"Alice Sykorova, M.D., Ph.D.","+420495 832 866","alice.sykorova@fnhk.cz",{"facility":60,"status":44,"city":61,"state":10,"zip":62,"country":47,"countryCode":10,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"University Hospital Olomouc","Olomouc","77520",{"type":49,"coordinates":64},[65,66],17.25175,49.59552,{"lat":66,"lon":65},[69],{"name":70,"role":34,"phone":71,"phoneExt":10,"email":72},"Vit Prochazka, prof. M.D.","+420588 442 878","prochazv@fnol.cz",{"facility":74,"status":44,"city":75,"state":10,"zip":76,"country":47,"countryCode":10,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"University Hospital Kralovske Vinohrady","Prague","10034",{"type":49,"coordinates":78},[79,80],14.42076,50.08804,{"lat":80,"lon":79},[83,84],{"name":29,"role":34,"phone":35,"phoneExt":10,"email":36},{"name":85,"role":34,"phone":86,"phoneExt":10,"email":87},"Katerina Klaskova, Ing.","+420267162880","katerina.klaskova@fnkv.cz",{"facility":89,"status":90,"city":75,"state":10,"zip":91,"country":47,"countryCode":10,"cosmosGeoPoint":92,"geoPoint":94,"contacts":10},"Charles University","ACTIVE_NOT_RECRUITING","12108",{"type":49,"coordinates":93},[79,80],{"lat":80,"lon":79},{"facility":96,"status":44,"city":75,"state":10,"zip":97,"country":47,"countryCode":10,"cosmosGeoPoint":98,"geoPoint":100,"contacts":101},"General University Hospital","12808",{"type":49,"coordinates":99},[79,80],{"lat":80,"lon":79},[102],{"name":103,"role":34,"phone":104,"phoneExt":10,"email":105},"Jan Koren, M.D.","+420224962541","jan.koren@vfn.cz",{"type":107,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[109,112,114,115,116],{"name":110,"class":111},"Charles University, Czech Republic","OTHER",{"name":113,"class":111},"General University Hospital, Prague",{"name":60,"class":111},{"name":43,"class":111},{"name":117,"class":111},"University Hospital, Motol","100536338","prognostic-significance-of-ctdna-in-hl-100536338",false,"NCT06263530","Prognostic Significance of ctDNA in HL","Prognostic Significance of Circulating Tumor DNA in Hodgkin Lymphoma","Inclusion Criteria:\n\n* Patients ≥ 18 years with newly histologically confirmed classical Hodgkin lymphoma (cHL) will be enrolled\n* signing the informed consent\n\nExclusion Criteria:\n\n* Pacients without signing the informed consent","ALL","18 Years",{"count":128,"type":129},500,"ESTIMATED","OBSERVATIONAL","Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \\\u003C60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and\u002For nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo\u002Fradiotherapy.",[133],"Prognostic Cancer Model",[135,136,137],"Hodgkin lymphoma","circulating tumor DNA","next generation sequencing","2024-02-08",{"date":140,"type":141},"2024-02-16","ACTUAL",{"date":143,"type":141},"2022-01-02",{"date":145,"type":129},"2027-12-31",{"name":5,"class":6},5]